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INTRODUCTION
Carcinoembryonic antigen (CEA) is a protein involved in 
cell adhesion.1 First described by Gold and Freedman,2 CEA 
measurement is used as a tumor marker to monitor colorectal 
carcinoma treatment, identify recurrences after surgical resec-
tion, and stage or localize cancer spread through measure-
ment of biological fluids.3 Rarely, CEA elevation can be asso-
ciated with other malignancies and disorders. In this report, 
a middle-aged man with a history of colon cancer presented 
with persistently elevated CEA after presumptive remission.
CASE REPORT
A 56-year-old male with poorly controlled hypertension 
and glycemia presented with recurrent episodes of pressure 
sensation in his chest, profuse sweating, and flushing for the 
past few months. Past medical history was significant for left 
adrenal pheochromocytoma status post left adrenalectomy 
10 years prior and colon cancer status post partial colectomy 
followed by chemotherapy with persistent CEA elevation 
of 400s ng/ml (normal range 0.0 - 4.7 ng/ml). Further testing, 
including whole body CT scan, PET scan, and gastrointesti-
nal scopes, failed to localize colon cancer recurrence. Physi-
cal examination revealed a palpable hard, non-tender nod-
ule in the left mid-antero-lateral compartment of the neck. 
Laboratory testing showed elevated 24-hour urinary meta-
nephrines with a markedly abnormal serum calcitonin level of 
7735 pg/ml (normal range is 10 pg/ml or less). CT scan of the 
abdomen confirmed a right adrenal nodule with positive up-
take on a metaiodobenzylguanidine (MIBG) scan. Thyroid so-
nography showed a calcified thyroid node in the left mid-an-
tero-lateral compartment of the neck. Genetic testing confirmed 
a mutant RET oncogene, confirming the clinical suspicion of 
multiple endocrine neoplasia syndrome type 2A (MEN 2A). 
Right adrenalectomy was performed, revealing an 8.5 cm 
tumor located in the adrenal medulla, consistent with pheo-
chromocytoma. Total thyroidectomy followed consistent with 
multifocal medullary thyroid carcinoma (MTC) and 18/18 
lymph nodes with metastatic medullary carcinoma. However, 
calcitonin was elevated persistently on routine follow-up af-
ter the surgery with 10250 pg/ml and CEA of 187 ng/ml. The 
follow-up measurements, a year later, were 9242 pg/ml and 
160 ng/ml for the calcitonin and CEA, respectively. Of note, 
the patient’s daughter also was diagnosed with MTC at the 
age of 16 after prophylactic thyroidectomy was performed.
DISCUSSION
Although of minimal use in detecting early colorectal can-
cer, high preoperative concentrations of CEA correlate with ad-
verse prognosis.4 Serial CEA measurements can detect recurrent 
colorectal cancer with a sensitivity of 80% and a specificity of 
70%.5 CEA is the most frequent indicator of recurrence in asymp-
tomatic patients.6,7 CEA levels also may be raised in medullary 
thyroid carcinoma8 as well as some non-neoplastic conditions 
like cirrhosis9 and hypothyroidism,10 as well as in smokers.11
History of bilateral pheochromocytoma, a thyroid mass, 
markedly elevated serum calcitonin level, and a persistently el-
evated CEA with a normal yearly colonoscopy, suggests that the 
elevated CEA, in this case, was due to MTC. CEA level also was 
found to be correlated with progression and prognosis of the 
MTC. A CEA level of less than 30 ng/mL is consistent with lo-
cal MTC and surgery might be curative in this situation. Levels 
more than 30.0 ng/mL indicate central and lateral (ipsilateral) 
lymph node metastases, whereas CEA levels more than 100.0 
ng/mL suggest lateral (contralateral) lymph node metastases 
and distant metastasis.12 CEA has additional importance in this 
specific disease as preoperative CEA levels may be helpful for 
determining the invasiveness of the surgery, the extent of lymph 
node dissection, thus the prognosis in patient with MTC.12
CONCLUSION
Patients with colorectal carcinoma often have higher lev-
els of CEA (above approximately 2.5 ng/mL) than healthy in-
dividuals.13 CEA commonly is used to identify recurrences 
after surgical resection.3 Bilateral pheochromocytoma, a thy-
roid mass, markedly elevated serum calcitonin level, and a 
persistently elevated CEA favored the diagnosis of MEN 2A 
syndrome over recurrence of colon cancer. In cases with per-
sistently elevated CEA with non-significant colonoscopies, 
suspicion should be high for other causes, especially if pa-
tient presentation was consistent with signs and symptoms 
of MEN 2 syndrome. Also, CEA signals the extent and the 
site of metastases and subsequently the surgical invasiveness.
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